作者: Mitsuyoshi Yoshimoto , Hiroaki Kurihara , Hirofumi Fujii
DOI: 10.1155/2015/842101
关键词:
摘要: During the past decade, efficacy of new molecular targeted drugs such as tyrosine kinase inhibitors (TKIs) and monoclonal antibodies has been proven worldwide, therapies have become mainstream in cancer therapy. However, clinical use these presents unexpected adverse effects or poor therapeutic effects. Therefore, we require diagnostic tools to estimate target molecule status tissues predict Although immunohistochemical, polymerase chain reaction (PCR) fluorescence situ hybridization (FISH) analyses biopsy samples are conventional popular for this purpose, imaging modalities positron emission tomography (PET) single photon computed (SPECT) also useful noninvasive estimation gene protein expression drug pharmacokinetics. In review, introduce radiolabeled TKIs, antibodies, their application therapy discuss issues probes.